AstraZeneca PLC (AZN.L) — Quality & forensics
As of 2026-10-26 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 48
- Quality 74
- Growth 46
- Balance sheet 47
- Cash quality 45
- Capital allocation 53
- Momentum 43
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the AZN.L chart & overview
FAQ · from the current data · as of 2026-10-26
Quick answers
What is AstraZeneca PLC's Closelooknet quality reading?
The composite reads 52/100 across 7 modules, as of 2026-10-26: valuation 48, quality 74, growth 46, balance sheet 47, cash quality 45, capital allocation 53, momentum 43. Closelooknet scores are research diary readings, not ratings or investment advice.
What is AstraZeneca PLC's Altman Z-Score?
2.85, which sits in the grey zone (1.81–2.99) as of 2026-10-26. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is AstraZeneca PLC's Piotroski F-Score?
9 of 9, as of 2026-10-26. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does AstraZeneca PLC's Beneish M-Score indicate?
-2.45 — below the −1.78 manipulation-risk threshold, as of 2026-10-26. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- LLY Eli Lilly and Companyindustry
- ORNAV.HE Orion Oyj Aindustry
- ORNBV.HE Orion Oyj Bindustry
- SAN.PA Sanofi SAindustry
- AMGN Amgen Incindustry
- GSK GlaxoSmithKline PLC ADRindustry
- BIIB Biogen Incindustry
- ABBV AbbVie Incindustry
- GILD Gilead Sciences Incindustry
- 002422.SHE Sichuan Kelun Pharmaceutical Co Ltdindustry
- PFE Pfizer Incindustry
- JNJ Johnson & Johnsonindustry
- OGN Organon & Coindustry
- BMY Bristol-Myers Squibb Companyindustry
- MRK Merck & Company Incindustry
- SNY Sanofi ADRindustry
- AZN AstraZeneca PLCindustry
- CMHC.SW COSMO N NVindustry
- ONT.L Oxford Nanopore Technologies Ltdsector
- CTEC.L ConvaTec Group PLCsector